Ganciclovir-resistant cytomegalovirus in organ transplant recipients. - Wikidata - awgldk - TriplyDB

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

http://www.wikidata.org/entity/Q44000196

about

Human cytomegalovirus resistance to antiviral drugs CMV: Prevention, Diagnosis and Therapy How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients Antiviral drug resistance: mechanisms and clinical implications Antiviral drug resistance of human cytomegalovirus.Management of cytomegalovirus infection and disease in liver transplant recipients.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients Current concepts on cytomegalovirus infection after liver transplantation The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro Ganciclovir-resistant cytomegalovirus infection in renal transplantation.Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients.Epigenetically repressing human cytomegalovirus lytic infection and reactivation from latency in THP-1 model by targeting H3K9 and H3K27 histone demethylases.Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir.Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.Strategies for managing cytomegalovirus in transplant recipients.Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.Cytomegalovirus infection and the gastrointestinal tract.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.De novo inflammatory bowel disease and its mimics after organ transplantation.Prevention of cytomegalovirus following solid organ transplantation: a literature review.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus.Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.Risk Factors and Outcomes of Ganciclovir Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection.Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin.Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients.Two-year post-transplantation cytomegalovirus DNAemia in asymptomatic kidney transplant recipients: incidence, risk factors, and outcome.

P2860

Q24556634-E06B83B3-6394-4375-A71B-0BB1F18E32F9 Q26824869-0EA9BD2B-2D9B-47B3-98E8-0E47DE28FDB4 Q28069489-BC3B569F-7D10-4357-82CC-08011C7D9EFC Q28282376-AA4920B2-D6F6-4B77-9608-02E96297DFB2 Q30430427-6C7E64DB-312A-4AB6-B6BB-1A827D0C2C5B Q33845124-5389A487-C92B-4866-9D08-D01F551D4DE1 Q33932079-2E601778-C4CC-4685-9585-DEFC73489AEC Q34390310-AD7169DB-B4D1-4321-B211-801499208687 Q35005190-9E0EFAE6-DDCB-4A45-AA20-305D646E9AB3 Q35227636-1704A178-2120-4AD1-B27E-F9C07147063C Q35598906-13BE6F2E-F7DD-4B59-BDE4-28A69F8412CA Q35692301-D099D347-FFEF-4900-B91B-469B2195437C Q35922545-8B1E7DA6-23D8-465F-B25E-0D4494034CC9 Q36346073-1A9C6A88-80AD-437F-96C8-4286198E9F0A Q36514890-97D9EE8C-0B1F-461C-9CA6-9F5DD75EB332 Q36728782-AB3E27F3-28AB-44C6-8A7E-7814FA5E5978 Q37036531-D08F27E7-F0FC-42BB-AAE5-3D21A6201C59 Q37222032-3D033D03-033A-4AE1-878D-8B6946CE66AC Q37409907-DDA4D36F-8002-49E2-A3BC-589089DC9CC7 Q37544353-FA7541CC-6CFC-486A-84CD-6FE797031FCE Q37773992-2C2498E7-EFF4-4E59-BD84-D5D7F70850D0 Q37962447-29BA4A2D-BB04-437F-A76C-08A221757700 Q38010341-5F4E10D8-BF5C-467D-958B-3FD122F8F0CC Q38067694-3FBF83AA-0013-401C-B27D-AE963D4B6C63 Q38105200-9672AA33-196B-40B4-BB99-3CEA2B734A7A Q38124439-1943856E-E333-47B0-98B4-5C0E65650D56 Q38364698-9834E08B-B9FB-4130-A9E9-AA5A8EF07D41 Q38415861-5413D5FD-22C5-4A6F-857E-679195ED59B1 Q38664637-CB99340F-8BD7-43AB-AFDA-D5E6E48557C1 Q38725677-4F74754C-63CB-4DF9-9955-53BB59AB5781 Q38834042-3104E5FC-6BF5-43E6-BEE1-9BB2891CF549 Q38875887-1CFABFB2-8FCA-49FA-95DE-9FC2E3101626 Q39502888-090802ED-2F82-49E0-8B37-3BA4DF97D2A3 Q40262029-5A816740-D3EC-4655-A697-FD75FCD6B826 Q40426465-583F6CCD-98EF-40D7-B684-B7497E3C9326 Q40483485-5B267D4A-8895-4D34-B0A4-FB2F9EBF462D Q40589966-32EAE464-937F-416F-9847-9BBB5C8E917C Q40745646-729C6A67-9361-4F15-B55D-19A170815E82 Q41099858-524B8AD6-CA27-47F8-BED4-FC545F15251C Q41177320-BEEBF5EF-5018-4FC6-83E7-8D3C57647960

P2860

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

http://www.wikidata.org/entity/Q44000196

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@en

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@nl

type

label

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@en

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@nl

prefLabel

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@en

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@nl

P1433

Q44000196-BE747E00-48AA-40A4-9CAC-6F1E085B6214

P1476

Q44000196-1A5109C5-4D13-43C0-9492-A9E1EBB9E2A4

P2093

Q44000196-348A78B1-06F3-422A-A922-B4F91B04EBD1

P2860

Q44000196-08A22535-DD3C-4A66-B85F-76118BEAE14A

Q44000196-0F65A19C-4C05-400E-8224-ED87C7601D73

Q44000196-13D30EC6-63E5-4A2D-A651-355C194F4D15

Q44000196-1A269703-9E1C-4B88-9CB8-144B2BF583FA

Q44000196-21E17EE4-CEE1-40C8-B43B-90648238563E

Q44000196-261E123E-6339-42ED-BAAE-A18598F42353

Q44000196-3C75D435-7559-4260-BBCD-329A9BBE116F

Q44000196-4996A5B2-C959-4339-8B17-408E1785D986

Q44000196-4DBC4FC8-3868-4D79-AD79-E6855784BE95

Q44000196-51A8A464-656A-4FB3-B4A2-C34ECC001661

P304

Q44000196-8BCB4C92-DEB0-464A-B6E7-A086143CAF56

P31

Q44000196-D8827920-1F11-4D98-A25A-C51AF1253C61

P356

Q44000196-DE8248D3-4BF2-4D94-8685-B3589C568454

P407

Q44000196-1FCF3D33-A7B0-4001-A908-37295786C806

P433

Q44000196-DCA2B544-D804-4E0A-903D-E110A654448E

P478

Q44000196-26CE1758-148E-4131-8DB8-3D35515C7D6F

P577

Q44000196-952DF68B-C08B-47ED-B4BC-82DCA2264AF1

P5875

Q44000196-2848FFC1-25E3-440B-B56E-12473557E422

P698

Q44000196-15592053-350A-4454-ABBC-261387B67C73

P921

Q44000196-B9808119-EBB6-48BA-85C7-E5618507856C

P356

P1433

Clinical Infectious Diseases

P1476

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

@en

P2093

Ajit P Limaye

http://www.w3.org/2001/XMLSchema#string

P2860

Antiviral drug resistance in human cytomegalovirus

Definitions of cytomegalovirus infection and disease in transplant recipients

Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.

Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma.

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.

Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient.

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor.

P304

866-872

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/342385

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11160769

http://www.w3.org/2001/XMLSchema#string

P698

12228824

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus